CN113082001B - 一种核酸递送系统及其制备方法和应用 - Google Patents
一种核酸递送系统及其制备方法和应用 Download PDFInfo
- Publication number
- CN113082001B CN113082001B CN202110572364.7A CN202110572364A CN113082001B CN 113082001 B CN113082001 B CN 113082001B CN 202110572364 A CN202110572364 A CN 202110572364A CN 113082001 B CN113082001 B CN 113082001B
- Authority
- CN
- China
- Prior art keywords
- nucleic acid
- delivery system
- acid delivery
- polyhydroxyalkanoate
- mixing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 93
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 93
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 93
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 239000002105 nanoparticle Substances 0.000 claims abstract description 66
- 239000005014 poly(hydroxyalkanoate) Substances 0.000 claims abstract description 29
- 229920000903 polyhydroxyalkanoate Polymers 0.000 claims abstract description 28
- 239000000463 material Substances 0.000 claims abstract description 25
- 150000001412 amines Chemical class 0.000 claims abstract description 20
- 239000003814 drug Substances 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 17
- 229940079593 drug Drugs 0.000 claims abstract description 9
- 239000000969 carrier Substances 0.000 claims abstract 2
- 108020004459 Small interfering RNA Proteins 0.000 claims description 49
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 32
- 239000000839 emulsion Substances 0.000 claims description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- 238000002156 mixing Methods 0.000 claims description 18
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 16
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 16
- 150000001875 compounds Chemical class 0.000 claims description 14
- 239000002904 solvent Substances 0.000 claims description 14
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 claims description 13
- 210000003022 colostrum Anatomy 0.000 claims description 12
- 235000021277 colostrum Nutrition 0.000 claims description 12
- 238000002604 ultrasonography Methods 0.000 claims description 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
- 239000003960 organic solvent Substances 0.000 claims description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 6
- 229920000962 poly(amidoamine) Polymers 0.000 claims description 5
- 239000000412 dendrimer Substances 0.000 claims description 4
- 229920000736 dendritic polymer Polymers 0.000 claims description 4
- 108020004999 messenger RNA Proteins 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- FHUDZSGRYLAEKR-UHFFFAOYSA-N 3-hydroxybutanoic acid;4-hydroxybutanoic acid Chemical compound CC(O)CC(O)=O.OCCCC(O)=O FHUDZSGRYLAEKR-UHFFFAOYSA-N 0.000 claims description 3
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 239000000872 buffer Substances 0.000 claims description 2
- 229950005499 carbon tetrachloride Drugs 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 239000007884 disintegrant Substances 0.000 claims description 2
- 239000003995 emulsifying agent Substances 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000013355 food flavoring agent Nutrition 0.000 claims description 2
- 239000003205 fragrance Substances 0.000 claims description 2
- 238000001415 gene therapy Methods 0.000 claims description 2
- 239000003906 humectant Substances 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 108091070501 miRNA Proteins 0.000 claims description 2
- 239000002679 microRNA Substances 0.000 claims description 2
- 230000003204 osmotic effect Effects 0.000 claims description 2
- 239000004014 plasticizer Substances 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 239000000375 suspending agent Substances 0.000 claims description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 claims description 2
- 239000002562 thickening agent Substances 0.000 claims description 2
- 239000000080 wetting agent Substances 0.000 claims description 2
- 239000006184 cosolvent Substances 0.000 claims 1
- 238000003760 magnetic stirring Methods 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 38
- 238000001890 transfection Methods 0.000 abstract description 16
- 210000003712 lysosome Anatomy 0.000 abstract description 12
- 230000001868 lysosomic effect Effects 0.000 abstract description 12
- 230000004700 cellular uptake Effects 0.000 abstract description 8
- -1 compound amine Chemical class 0.000 abstract description 8
- 101710163270 Nuclease Proteins 0.000 abstract description 5
- 231100000135 cytotoxicity Toxicity 0.000 abstract description 5
- 230000003013 cytotoxicity Effects 0.000 abstract description 5
- 230000015556 catabolic process Effects 0.000 abstract description 4
- 238000006731 degradation reaction Methods 0.000 abstract description 4
- 238000011068 loading method Methods 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 29
- 206010018910 Haemolysis Diseases 0.000 description 11
- 230000008588 hemolysis Effects 0.000 description 11
- 210000001163 endosome Anatomy 0.000 description 9
- 239000001963 growth medium Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 230000008045 co-localization Effects 0.000 description 8
- 239000002270 dispersing agent Substances 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 238000012258 culturing Methods 0.000 description 6
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 229920001661 Chitosan Polymers 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 238000002784 cytotoxicity assay Methods 0.000 description 5
- 231100000263 cytotoxicity test Toxicity 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000007910 cell fusion Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 238000009210 therapy by ultrasound Methods 0.000 description 4
- RRWWOSSPAGCJFO-UHFFFAOYSA-N 3-hydroxybutanoic acid;3-hydroxyhexanoic acid Chemical compound CC(O)CC(O)=O.CCCC(O)CC(O)=O RRWWOSSPAGCJFO-UHFFFAOYSA-N 0.000 description 3
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 3
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 3
- 210000000845 cartilage Anatomy 0.000 description 3
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 108010054624 red fluorescent protein Proteins 0.000 description 3
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 3
- 238000000527 sonication Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 210000001612 chondrocyte Anatomy 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 108091006047 fluorescent proteins Proteins 0.000 description 2
- 102000034287 fluorescent proteins Human genes 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229920000520 poly(3-hydroxybutyrate-co-3-hydroxyvalerate) Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 102000006833 Multifunctional Enzymes Human genes 0.000 description 1
- 108010047290 Multifunctional Enzymes Proteins 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 229920002334 Spandex Polymers 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000002479 lipoplex Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- HEGSGKPQLMEBJL-UHFFFAOYSA-N n-octyl beta-D-glucopyranoside Natural products CCCCCCCCOC1OC(CO)C(O)C(O)C1O HEGSGKPQLMEBJL-UHFFFAOYSA-N 0.000 description 1
- 239000002539 nanocarrier Substances 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 239000004759 spandex Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/595—Polyamides, e.g. nylon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
组别 | 粒径(nm)(n=3) | PDI(n=3) | Zeta电位(n=3) |
实施例1 | 181.5±6.6 | 0.055±0.025 | -11.20±1.71 |
实施例2 | 160.6±1.3 | 0.150±0.049 | +11.90±5.92 |
实施例3 | 224.4±2.9 | 0.262±0.039 | -9.54±9.79 |
实施例4 | 181.5±5.5 | 0.162±0.053 | +9.88±4.62 |
实施例5 | 178.6±2.5 | 0.175±0.123 | +5.80±1.25 |
实施例6 | 164.3±2.5 | 0.190±0.102 | +7.52±2.52 |
实施例7 | 261.3±2.6 | 0.106±0.010 | +19.80±1.05 |
实施例8 | 248.3±7.3 | 0.099±0.031 | +0.99±4.46 |
粒径(nm) | 第1天 | 第7天 | 第10天 | 第14天 |
实施例1 | 181.5±6.6 | 184.1±4.0 | 186.3±5.8 | 349.0±64.6 |
实施例2 | 160.6±1.3 | 168.5±2.3 | 159.5±5.2 | 190.3±5.6 |
实施例3 | 224.4±2.9 | 225.6±6.2 | 231.2±4.1 | 253.1±2.5 |
实施例4 | 181.5±5.5 | 185.2±3.2 | 187.5±3.2 | 195.3±4.1 |
实施例5 | 178.6±2.5 | 182.3±3.4 | 183.4±2.3 | 190.5±22.8 |
实施例6 | 164.3±2.5 | 168.3±2.3 | 169.2±1.4 | 173.2±13.9 |
实施例7 | 261.3±2.6 | 265.3±2.8 | 167.2±1.9 | 180.2±3.9 |
实施例8 | 248.3±7.3 | 258.6±33.3 | 236.4±5.7 | 262.1±14.6 |
Zeta电位 | 第1天 | 第7天 | 第10天 | 第14天 |
实施例1 | -11.20±1.71 | -10.99±5.05 | -8.04±4.15 | -11.67±2.57 |
实施例2 | +11.90±5.92 | +10.85±3.26 | +12.03±2.36 | +15.20±5.43 |
实施例3 | -9.54±9.79 | -5.68±10.23 | -12.65±8.15 | -15.15±5.26 |
实施例4 | +9.88±4.62 | +12.02±5.23 | +15.02±2.78 | +10.89±5.93 |
实施例5 | +5.80±1.25 | +6.23±2.51 | +6.15±5.23 | +11.56±1.98 |
实施例6 | +7.52±2.52 | +10.25±3.25 | +11.23±3.89 | +15.26±3.95 |
实施例7 | +19.80±1.05 | +20.36±5.17 | +26.2±6.19 | +21.83±4.15 |
实施例8 | +0.99±4.46 | +3.65±2.22 | +14.93±1.72 | +13.91±7.45 |
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110572364.7A CN113082001B (zh) | 2021-05-25 | 2021-05-25 | 一种核酸递送系统及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110572364.7A CN113082001B (zh) | 2021-05-25 | 2021-05-25 | 一种核酸递送系统及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113082001A CN113082001A (zh) | 2021-07-09 |
CN113082001B true CN113082001B (zh) | 2023-05-26 |
Family
ID=76664403
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110572364.7A Active CN113082001B (zh) | 2021-05-25 | 2021-05-25 | 一种核酸递送系统及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113082001B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017036398A1 (zh) * | 2015-09-01 | 2017-03-09 | 苏州瑞博生物技术有限公司 | 一种小干扰核酸和药物组合物及其用途 |
CN111265669A (zh) * | 2020-03-31 | 2020-06-12 | 华南理工大学 | 一种核酸转运用载体组合物及其在制备小干扰rna药物中的应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7030097B1 (en) * | 1999-07-14 | 2006-04-18 | Cornell Research Foundation, Inc. | Controlled nucleic acid delivery systems |
AUPQ259399A0 (en) * | 1999-09-01 | 1999-09-23 | Lustre Investments Pte Ltd | Therapeutic agents |
CN102174184B (zh) * | 2011-01-14 | 2012-11-21 | 中国科学院广州生物医药与健康研究院 | 一种生物可降解的聚合物及其制备方法以及核酸药物运输载体 |
CN102786695B (zh) * | 2012-05-08 | 2014-04-23 | 中国科学院广州生物医药与健康研究院 | 两亲性三嵌段聚合物及其制备方法和siRNA药物载体 |
CN111514302B (zh) * | 2020-04-20 | 2023-06-23 | 中国医学科学院北京协和医院 | PHBVHHx纳米缓释载体及其应用 |
-
2021
- 2021-05-25 CN CN202110572364.7A patent/CN113082001B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017036398A1 (zh) * | 2015-09-01 | 2017-03-09 | 苏州瑞博生物技术有限公司 | 一种小干扰核酸和药物组合物及其用途 |
CN111265669A (zh) * | 2020-03-31 | 2020-06-12 | 华南理工大学 | 一种核酸转运用载体组合物及其在制备小干扰rna药物中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN113082001A (zh) | 2021-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Liu et al. | Star-shaped cyclodextrin-poly (l-lysine) derivative co-delivering docetaxel and MMP-9 siRNA plasmid in cancer therapy | |
CN110448696B (zh) | 基于盐藻外泌体靶向药物递送载体的制备方法与应用 | |
Yamashita et al. | A novel bubble liposome and ultrasound-mediated gene transfer to ocular surface: RC-1 cells in vitro and conjunctiva in vivo | |
Kwon et al. | In vivo time-dependent gene expression of cationic lipid-based emulsion as a stable and biocompatible non-viral gene carrier | |
CN107022571A (zh) | 一种转染Jurkat细胞的方法 | |
CN110123754A (zh) | 一种靶向作用于树突细胞的苍耳亭纳米胶束及制备方法和应用 | |
CN113082001B (zh) | 一种核酸递送系统及其制备方法和应用 | |
CA2704236C (en) | Nucleic acid complex and nucleic acid delivery composition | |
CN112342246A (zh) | 一种非病毒基因载体系统及其制备方法和应用 | |
JP2023091069A (ja) | 核酸導入キャリア、核酸導入キャリアセット、核酸導入組成物及び核酸導入方法 | |
CN116510035A (zh) | 一种实现核酸物质递送的纳米递送系统、其制备方法及应用 | |
JP2022187826A (ja) | 核酸送達キャリア、その製造方法、核酸送達方法、細胞製造方法、細胞検出方法及びキット | |
CN105861561A (zh) | 红色罗丹明染料示踪基因纳米载体的制备方法及应用 | |
CN115715186A (zh) | 含核酸与阳离子共聚物的复合物的纳米粒子及其制备方法、用于基因转移至细胞中的用途 | |
Zhang et al. | Chiral Graphene Quantum Dots Enhanced Drug Loading into Exosomes | |
CN112370435A (zh) | 一种靶向核壳结构载药纳米颗粒及其制备方法 | |
US9090912B1 (en) | Nucleic acid complex and nucleic acid-delivering composition | |
US20210032589A1 (en) | Methods and devices for the isolation of subcellular components | |
CN111297828A (zh) | 一种活性氧响应纳米给药系统及其制备方法和用途 | |
CN111658785B (zh) | 一种基因载体及其制备方法和应用 | |
CN116082179B (zh) | 基于内源性二羧酸的可电离脂质及其制备方法与应用 | |
CN117547617A (zh) | 一种具有肝脏靶向性的核酸药物递送系统及其制备方法 | |
KR100514092B1 (ko) | 양이온성 고분자 물질과 음이온성 고분자 물질을 이용한 새로운 다중 유전자 전달 복합체 | |
CN115919795A (zh) | 一种非界面自组装微囊及其制备方法和应用 | |
CN116650669A (zh) | 一种壳-核结构的CRISPR/Cas9递送系统及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240315 Address after: Room 1102, Building 1, No. 188 Kaiyuan Avenue, Huangpu District, Guangzhou City, Guangdong Province, 510530 Patentee after: Danta Zhouzi Pharmaceutical Technology (Guangzhou) Co.,Ltd. Country or region after: China Address before: 510530 open source Avenue 190, Science City, Guangzhou, Guangdong Patentee before: GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES Country or region before: China |
|
TR01 | Transfer of patent right |